Company
Clarity Pharmaceuticals Ltd
ASX:CU6
Clinical-stage radiopharmaceutical company. Its SAR Technology platform pairs copper-64 (imaging) and copper-67 (therapy) with the same targeting molecule, so a single agent can both find and treat a tumour. Three candidates: SAR-bisPSMA (prostate cancer, lead), SAR-Bombesin (prostate and other PSMA-negative tumours) and SARTATE (neuroendocrine tumours). Relevance to the variis universe is late-life cancer detection and treatment: prostate and neuroendocrine cancers are strongly age-associated, and the company's clinical case rests on detecting recurrent disease at low PSA levels, i.e. earlier than standard-of-care imaging. Nothing in the pipeline targets ageing biology directly. Qualifies on limbs (a) and (b): ASX-listed and Australian-headquartered. Note it is pre-revenue and pre-approval; no product has regulatory approval.
At a glance
- Listing
- ASX:CU6
- Category
- Diagnostics
- Headquarters
- Eveleigh, Sydney, NSW, Australia
- Market cap
- ~A$866m (17 July 2026, stockanalysis.com; share price A$2.32)
Thesis
Why it is in this universe
- Category
- Diagnostics
- Market
- Australia
- Recent inflection
- 14 October 2025: Clarity announced the investigator-initiated Phase II Co-PSMA trial met its primary endpoint, with 64Cu-SAR-bisPSMA PET/CT detecting significantly more lesions per patient than standard-of-care 68Ga-PSMA-11 PET/CT in 50 post-prostatectomy patients with low PSA (company announcement, claritypharmaceuticals.com). This was followed on 14 April 2026 by a commercial manufacturing agreement with Nucleus RadioPharma for 64Cu-SAR-bisPSMA.
- Services
- None recorded
- People tracked
- 2
Market data
Listing and scale
| Metric | Detail |
|---|---|
| Exchange | ASX |
| Ticker | ASX:CU6 |
| Secondary listing | None |
| Market cap | ~A$866m (17 July 2026, stockanalysis.com; share price A$2.32) |
| Status | Listed and trading |
Editor's noteA listing or financing event is not a clinical result. variis grades evidence on the linked protocol, not the share price.
Get in touch
Contact
- Address
- Eveleigh, Sydney, NSW, Australia
- Phone
- No public number published
- No public address published
Offering
What it sells today
No commercial services are recorded for this company yet.
People
Who variis tracks here (2)
variis does not publish portraits of named individuals without a licence to do so.
Recent inflection
What moved lately
14 October 2025: Clarity announced the investigator-initiated Phase II Co-PSMA trial met its primary endpoint, with 64Cu-SAR-bisPSMA PET/CT detecting significantly more lesions per patient than standard-of-care 68Ga-PSMA-11 PET/CT in 50 post-prostatectomy patients with low PSA (company announcement, claritypharmaceuticals.com). This was followed on 14 April 2026 by a commercial manufacturing agreement with Nucleus RadioPharma for 64Cu-SAR-bisPSMA.
Common questions
- Why does variis track Clarity Pharmaceuticals Ltd?
- Clinical-stage radiopharmaceutical company. Its SAR Technology platform pairs copper-64 (imaging) and copper-67 (therapy) with the same targeting molecule, so a single agent can both find and treat a tumour. Three candidates: SAR-bisPSMA (prostate cancer, lead), SAR-Bombesin (prostate and other PSMA-negative tumours) and SARTATE (neuroendocrine tumours). Relevance to the variis universe is late-life cancer detection and treatment: prostate and neuroendocrine cancers are strongly age-associated, and the company's clinical case rests on detecting recurrent disease at low PSA levels, i.e. earlier than standard-of-care imaging. Nothing in the pipeline targets ageing biology directly. Qualifies on limbs (a) and (b): ASX-listed and Australian-headquartered. Note it is pre-revenue and pre-approval; no product has regulatory approval.
- Is Clarity Pharmaceuticals Ltd publicly listed?
- Yes. It trades as ASX:ASX:CU6. Market capitalisation is in the ~A$866m (17 July 2026, stockanalysis.com; share price A$2.32) range, recorded as a dated snapshot rather than a live quote.
- Where is Clarity Pharmaceuticals Ltd based?
- Eveleigh, Sydney, NSW, Australia
- Is Clarity Pharmaceuticals Ltd still trading?
- Clarity Pharmaceuticals Ltd is recorded as actively trading.
Keep reading
Related coverage from the newsroom.
Sources
What this profile is built on
- Clarity Pharmaceuticals: Radiopharmaceutical Therapies and Imaging (HQ address and SAR Technology pipeline) · Clarity Pharmaceuticals
- Clarity Pharmaceuticals Ltd (ASX:CU6) Market Cap · StockAnalysis
- Co-PSMA trial achieves primary endpoint · Clarity Pharmaceuticals
- Clarity signs a Commercial Manufacturing Agreement for Cu-64 SAR-bisPSMA with Nucleus RadioPharma · PR Newswire
Every entity profile on variis is sourced. Not investment advice.